399 related articles for article (PubMed ID: 35156271)
1. Mucormycosis: The hidden and forgotten disease.
Darwish RM; AlMasri M; Al-Masri MM
J Appl Microbiol; 2022 Jun; 132(6):4042-4057. PubMed ID: 35156271
[TBL] [Abstract][Full Text] [Related]
2. Breaking the Mold: A Review of Mucormycosis and Current Pharmacological Treatment Options.
Riley TT; Muzny CA; Swiatlo E; Legendre DP
Ann Pharmacother; 2016 Sep; 50(9):747-57. PubMed ID: 27307416
[TBL] [Abstract][Full Text] [Related]
3. Part 2: mucormycosis: focus on therapy.
Lynch JP; Zhanel GG
Expert Rev Anti Infect Ther; 2023; 21(7):737-748. PubMed ID: 37300820
[TBL] [Abstract][Full Text] [Related]
4. COVID-19 Associated Rhino-Orbital-Cerebral Mucormycosis: Clinical Features, Antifungal Susceptibility, Management and Outcome in a Tertiary Hospital in Iran.
Abdorahimi M; Pakdel F; Salehi M; Alcazar-Fuoli L; Hashemi SJ; Daie Ghazvini R; Ahmadkhani F; Ahmadikia K; Abdollahi A; Debran JCS; Tabari A; Farrokh F; Mousavand A; Afarinesh Khaki P; Salami Khaneshan A; Ibrahim AS; Khodavaisy S
Mycopathologia; 2023 Oct; 188(5):783-792. PubMed ID: 37672164
[TBL] [Abstract][Full Text] [Related]
5. An extensive review on antifungal approaches in the treatment of mucormycosis.
Chaudhari HS; Palkar OS; Abha Mishra KM; Sethi KK
J Biochem Mol Toxicol; 2023 Sep; 37(9):e23417. PubMed ID: 37345721
[TBL] [Abstract][Full Text] [Related]
6. Mucormycosis.
Steinbrink JM; Miceli MH
Infect Dis Clin North Am; 2021 Jun; 35(2):435-452. PubMed ID: 34016285
[TBL] [Abstract][Full Text] [Related]
7. Molecular characterization and in vitro antifungal susceptibility of 80 clinical isolates of mucormycetes in Delhi, India.
Chowdhary A; Kathuria S; Singh PK; Sharma B; Dolatabadi S; Hagen F; Meis JF
Mycoses; 2014 Dec; 57 Suppl 3():97-107. PubMed ID: 25250768
[TBL] [Abstract][Full Text] [Related]
8. [Expert consensus on diagnosis and treatment of severe COVID-19 associated pulmonary
;
Zhonghua Jie He He Hu Xi Za Zhi; 2024 Jan; 47(1):10-23. PubMed ID: 38062689
[TBL] [Abstract][Full Text] [Related]
9. Epidemiology and Antifungal Susceptibilities of Mucoralean Fungi in Clinical Samples from the United States.
Badali H; Cañete-Gibas C; McCarthy D; Patterson H; Sanders C; David MP; Mele J; Fan H; Wiederhold NP
J Clin Microbiol; 2021 Aug; 59(9):e0123021. PubMed ID: 34232068
[TBL] [Abstract][Full Text] [Related]
10. Mucormycosis: New Developments into a Persistently Devastating Infection.
Danion F; Aguilar C; Catherinot E; Alanio A; DeWolf S; Lortholary O; Lanternier F
Semin Respir Crit Care Med; 2015 Oct; 36(5):692-705. PubMed ID: 26398536
[TBL] [Abstract][Full Text] [Related]
11. Our 2014 approach to mucormycosis.
Tacke D; Koehler P; Markiefka B; Cornely OA
Mycoses; 2014 Sep; 57(9):519-24. PubMed ID: 24829170
[TBL] [Abstract][Full Text] [Related]
12. Antifungal combinations in Mucorales: A microbiological perspective.
Schwarz P; Cornely OA; Dannaoui E
Mycoses; 2019 Sep; 62(9):746-760. PubMed ID: 30830980
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy in Mucormycosis: Current evidence from the world literature, a mini review.
Meena DS; Kumar D; Bohra GK
J Mycol Med; 2023 Mar; 33(1):101332. PubMed ID: 36270213
[TBL] [Abstract][Full Text] [Related]
14. Utility of itraconazole and terbinafine in mucormycosis: a proof-of-concept analysis.
Gupta P; Malhotra HS; Saxena P; Singh R; Shukla D; Hasan MS; Verma V; Banerjee G; Puri B; Dandu H
J Investig Med; 2022 Apr; 70(4):914-918. PubMed ID: 35078866
[TBL] [Abstract][Full Text] [Related]
15. A prospective study of mucormycosis in north India: experience from a tertiary care hospital.
Bala K; Chander J; Handa U; Punia RS; Attri AK
Med Mycol; 2015 Apr; 53(3):248-57. PubMed ID: 25587084
[TBL] [Abstract][Full Text] [Related]
16. Increasing incidence of mucormycosis in a large Spanish hospital from 2007 to 2015: Epidemiology and microbiological characterization of the isolates.
Guinea J; Escribano P; Vena A; Muñoz P; Martínez-Jiménez MDC; Padilla B; Bouza E
PLoS One; 2017; 12(6):e0179136. PubMed ID: 28591186
[TBL] [Abstract][Full Text] [Related]
17. Current treatments against mucormycosis and future directions.
Smith C; Lee SC
PLoS Pathog; 2022 Oct; 18(10):e1010858. PubMed ID: 36227854
[TBL] [Abstract][Full Text] [Related]
18. Clinical and Mycologic Characteristics of Emerging Mucormycosis Agent Rhizopus homothallicus.
Rudramurthy SM; Singh S; Kanaujia R; Chaudhary H; Muthu V; Panda N; Pandey A; Thakur S; Kaur H; Ghosh A; Agarwal R; Chakrabarti A
Emerg Infect Dis; 2023 Jul; 29(7):1313-1322. PubMed ID: 37347535
[TBL] [Abstract][Full Text] [Related]
19. Mucormycosis in Africa: Epidemiology, diagnosis and treatment outcomes.
Osaigbovo II; Ekeng BE; Davies AA; Oladele RO
Mycoses; 2023 Jul; 66(7):555-562. PubMed ID: 36856432
[TBL] [Abstract][Full Text] [Related]
20. A case of mistaken identity:
Chen AJ; Ediriwickrema LS; Verma R; Vavinskaya V; Shaftel S; Deconde AS; Korn BS; Kikkawa DO; Liu CY
Orbit; 2021 Dec; 40(6):521-524. PubMed ID: 32862746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
